What is MYO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.06B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MYO?

P/E (TTM) is n/a and 52-week range is $0.60 to $1.89 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MYO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MYO?

The company profile lists revenue (TTM) near $39M, net income (TTM) near $-1.31B, EPS (TTM) near $-0.34 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Myomo Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boston, Massachusetts, US, 38.6M shares outstanding, ISIN US62857J2015 when available from company profile and filing metadata.

Myomo Inc

$MYO

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$1.43

+1.42%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Myomo, Inc. is a wearable medical robotics company, which engages in the business of developing, designing, and producing myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 194 full-time employees. The company went IPO on 2017-06-12. The firm develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.

Employees

194

Website

myomo.com/

IPO

2017-06-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)